Many patients taking GLP-1 medications like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) experience digestive side effects including nausea, bloating, and altered bowel habits
However, as a precaution, semaglutide is not recommended for individuals who have: A personal or family history of Medullary Thyroid Carcinoma (MTC)
"Nutrition is not an afterthought its a therapeutic partner." Eating right helps patients sustain weight loss and preserve lean mass, she added
Providers like United Healthcare, Cigna, and Blue Cross Blue Shield, among others, cover semaglutide with prior authorization based on specific conditions
Alluvi Retatrutide BPC-157 & TB-500 40mg Premium Research-Grade Peptide Blend The Alluvi Retatrutide BPC-157 & TB-500 40mg is a premium research-grade peptide blend developed for scientific, educational, and laboratory research applications
Most research-planning cycles run 8-12 weeks on, followed by 4 weeks off